Drugs / iSCIB1+
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07815574 | Dec 2026 → Dec 2028 expected | cutaneous melanoma | Scancell Ltd | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-08-19 | Scancell Ltd | Regulatory Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma scancell.co.uk ↗
Scancell Holdings plc (AIM: SCLP), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that the MHRA has granted a Clinical Trial Authorization (CTA) for the Phase 3 registrational trial of its lead ImmunoBody® iSCIB1+ in patients with advanced melanoma. |
| 2026-04-28 | Scancell Ltd | Regulatory Scancell Receives FDA Fast Track Designation for iSCIB1+ scancell.co.uk ↗
Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead ImmunoBody® iSCIB1+ for the treatment of advanced melanoma. |
| 2026-01-26 | Scancell Ltd | Regulatory Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma scancell.co.uk ↗
Scancell Holdings plc ( AIM: SCLP ), the developer of active immunotherapies to treat cancer , announces the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a registrational Phase 3 trial of its iSCIB1+ Immunobody® in advanced melanoma, with progression free survival as the agreed surrogate endpoint. |
| 2025-12-09 | Scancell Ltd | Results Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ scancell.co.uk ↗
Updated data in this cohort show progression free survival (PFS) was 74% at 16 months in the target population. |
| 2025-11-07 | Scancell Ltd | Results Scancell to present positive Phase 2 data on Immunobody ® iSCIB1+ in late-stage melanoma at SITC 2025 scancell.co.uk ↗ |
| 2025-07-22 | Scancell Ltd | Results Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody ® iSCIB1+ scancell.co.uk ↗ |
| 2024-01-17 | Scancell Ltd | Regulatory MHRA approval to add a third cohort using iSCIB1+ to the SCOPE trial scancell.co.uk ↗
MHRA approval to add a third cohort using iSCIB1+ to the SCOPE trial |
| 2023-11-28 | Scancell Ltd | Regulatory Update on SCOPE trial scancell.co.uk ↗
Scancell has also received MHRA correspondence requesting a preclinical mouse safety study with iSCIB1+ prior to resubmission of the a |
| 2023-09-19 | Scancell Ltd | Regulatory Scancell announces positive data from the first stage in its Phase 2 SCOPE trial with SCIB1 cancer vaccine delivered by needle free injection for advanced melanoma scancell.co.uk ↗ |
All press releases naming this drug 13 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iSCIB1+ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07815574 ↗ |
| Modality | Vaccine | “DNA-based therapeutic cancer vaccine” NCT07815574 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT07815574 ↗ |